Fluoropyrimidine chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. In an international retrospective study (13 centres in 6 countries), it was shown that switching to another (newly registered in metastatic colorectal cancer) fluoropyrimidine can be an option to allow continuation of this essential component of chemotherapy and thus not lose a treatment line.
The colleagues at Meducom were asked to provide support with the development and editing of the manuscript of this pivotal study for a new indication of a drug in metastatic colorectal cancer.
Link: https://www.esmoopen.com/action/showPdf?pii=S2059-7029%2822%2900048-5